Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Timing of BR55 CEUS in Pre-menopausal Women
NCT04248153Phase 2Terminated
- Sponsor
- Bracco Diagnostics Inc.
- Start
- Oct 2019
- Primary completion
- Feb 2020
- Modality
- Nanoparticles, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of perfluorobutane/nitrogen lipopeptide-coated microbubbles in ovarian cancer (2 arms), sponsored by Bracco Diagnostics Inc. Primary endpoint: Adverse Events. Started Oct 2019; status: terminated.
02
Drugs
perfluorobutane/nitrogen lipopeptide-coated microbubbles
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04248153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04248153.